Patents by Inventor Tamara KORITAROV

Tamara KORITAROV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metal oxide nanoparticle for cell lysis
    Patent number: 10525146
    Abstract: A nanostructure comprises a MOX NP and a bidentate ligand on a surface of the MOX NP. A cancer recognition molecule is covalent coupled to the surface of the MOX NP via the bidentate ligand. A biocatalyst is also coupled to the surface of the MOX nanoparticle via the bidentate ligand. The cancer recognition molecule includes a structure configured to selectively recognize a corresponding antigen on a surface of a cancer cell and bind to the antigen. The biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons. The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state. The reactive oxygen species lyse or cause apoptosis in the cancer cells in situ. The biocatalyst includes luciferase and the light emitting compound includes luciferin.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: January 7, 2020
    Assignee: UChicago Argonne, LLC
    Inventors: Tijana Rajh, Elena A. Rozhkova, Harry C. Fry, Nada Dimitrijevic, Tamara Koritarov
  • METAL OXIDE NANOPARTICLE FOR CELL LYSIS
    Publication number: 20190240347
    Abstract: A nanostructure comprises a MOX NP and a bidentate ligand on a surface of the MOX NP. A cancer recognition molecule is covalent coupled to the surface of the MOX NP via the bidentate ligand. A biocatalyst is also coupled to the surface of the MOX nanoparticle via the bidentate ligand. The cancer recognition molecule includes a structure configured to selectively recognize a corresponding antigen on a surface of a cancer cell and bind to the antigen. The biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons. The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state. The reactive oxygen species lyse or cause apoptosis in the cancer cells in situ. The biocatalyst includes luciferase and the light emitting compound includes luciferin.
    Type: Application
    Filed: April 16, 2019
    Publication date: August 8, 2019
    Inventors: Tijana RAJH, Elena A. ROZHKOVA, Harry C. FRY, Nada DIMITRIJEVIC, Tamara KORITAROV, Bartosz Gryzbowski
  • METAL OXIDE NANOPARTICLE FOR CELL LYSIS
    Publication number: 20180036426
    Abstract: A nanostructure comprises a MOX NP and a bidentate ligand on a surface of the MOX NP. A cancer recognition molecule is covalent coupled to the surface of the MOX NP via the bidentate ligand. A biocatalyst is also coupled to the surface of the MOX nanoparticle via the bidentate ligand. The cancer recognition molecule includes a structure configured to selectively recognize a corresponding antigen on a surface of a cancer cell and bind to the antigen. The biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons. The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state. The reactive oxygen species lyse or cause apoptosis in the cancer cells in situ. The biocatalyst includes luciferase and the light emitting compound includes luciferin.
    Type: Application
    Filed: March 31, 2016
    Publication date: February 8, 2018
    Inventors: Tijana RAJH, Bartosz GRYZBOWSKI, Elena A. ROZHKOVA, Harry C. FRY, Nada DIMITRIJEVIC, Tamara KORITAROV